Paxlovid And Vyndaqel Will Fall And Readouts Will Deliver Hope

AN
AnalystLowTarget
AnalystLowTarget
Not Invested
Consensus Narrative from 22 Analysts
Published
08 Apr 25
Updated
14 Jul 25
AnalystLowTarget's Fair Value
US$24.57
4.4% undervalued intrinsic discount
14 Jul
US$23.49
Loading
1Y
-21.0%
7D
-3.4%

Author's Valuation

US$24.6

4.4% undervalued intrinsic discount

AnalystLowTarget Fair Value

Shared on30 Apr 25
Fair value Increased 3.00%

AnalystLowTarget has increased revenue growth from -3.2% to -2.9%.

Shared on23 Apr 25
Fair value Decreased 6.73%

AnalystLowTarget has increased revenue growth from -2.9% to -3.2%.

Shared on16 Apr 25
Fair value Decreased 1.77%

AnalystLowTarget made no meaningful changes to valuation assumptions.

Shared on10 Apr 25
Fair value Increased 13%

AnalystLowTarget has increased revenue growth from -2.0% to -2.9%.